SD HEALTHCARE
Recent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...
Psychosis Drug Also Shows Promise in Dementia Cases
Nuplazid Nets $94.6 Million In Q3 SalesA drug from Acadia Pharmaceuticals made dementia patients nearly three times less likely to relapse into psychosis.San Diego Companies Find Deals and Dollars at Health Conference
Two DNA sequencing companies raised more than $140 million combined, Daré Bioscience inked a potential commercialization deal worth up to $310 million, and Human Longevity sold its cancer division for $37 million, and separately, acquired a company.
Neurocrine Gains Option to License Epilepsy Drug; Deal Worth up to $412M
San Diego-based Neurocrine could buy the rights to yet another experimental epilepsy drug, per a recently announced agreement that could be worth up to $412 million.
DNA Sequencing Company Element Biosciences Raises $80.3M Round
Element Biosciences, another San Diego upstart that’s trying to make DNA technology more accessible, recently raised an $80.3 million round.
Tandem Diabetes Software Gets FDA OK
Closed-Loop System Controls Low and High Blood Sugar.
Epirium to Take on Muscle Diseases, Aging
BIOTECH: Company focused on mitochondria health, raises $85M round
Boosting ambitious plans, Epirium recently secured an $85 million Series A round, amid greater investment in muscle therapies.
Foundation Readies To Take On Ultra-Rare Diseases
Former Ionis CEO To Take Helm At Nonprofit.
Toolbox Medical Gets Cos. to Next Level
DEVICE: Product Development, CRO Services Focus on Diagnostics
Point-of-care diagnostic testing, which allows consumers and professionals to get quick lab-quality test results within minutes, has become a huge business.
Medical Device Cos. Applaud Tax Repeal
HEALTH: Excise Tax Was an ACA Financing Mechanism
A recently signed federal spending bill repealed a 2.3% excise tax on medical device makers that was scheduled to resume this month, a boon to San Diego’s medtech industry.
With $4M in Funding, n-Lorem Foundation to Take on Rare Genetic Diseases
After three decades helming Carlsbad’s Ionis Pharmaceuticals, Stanley Crooke stepped down at the end of 2019. Retirement isn’t for him, it seems.
PharmAkea to Merge with Galecto
San Diego’s PharmAkea is merging with Denmark-based Galecto, a deal the companies said would combine overlapping drug development programs aimed at cancer and fibrosis.
Regulatory Hurdle Too High for Illumina
TECH: Co. Scraps Planned $1.2 Billion PacBio Acquisition
San Diego’s Illumina will no longer buy Pacific Biosciences for $1.2 billion, a decision the companies mutually reached following antitrust action on both sides of the pond. Pacific Biosciences, or PacBio, had the potential to add another dimension to Illumina’s DNA-reading technology that’s the backbone of everything from ancestry tests to prenatal screening. But last month, the U.S. Federal Trade Commission moved to block the transaction, and the U.K.’s Competition and Markets Authority in October said it might do the same. $98M Breakup Fee Per a Jan. 2 announcement, Illumina will pay a $98 million break-up fee to PacBio. But PacBio must repay the money if it strikes an agreement to be acquired by Sept. 30 and consummates the deal within two years. Illumina climbed to the top of the DNA sequencing market with short-read sequencing that amplifies snippets of DNA. Pacific Biosciences, or Pac
Organovo and Tarveda to Merge
Deal To Give Tarveda Access to Nasdaq
San Diego-based Organovo last summer put itself up for sale, after its implantable liver program failed a clinical trial.
Illumina, Pacific Biosciences Call Off $1.2B Deal
San Diego’s Illumina will no longer buy Pacific Biosciences for $1.2 billion, a decision the companies reached following antitrust action on both sides of the pond.
Organovo and Tarveda Therapeutics Agree to Merge
Recently, publicly-traded Organovo and Tarveda Therapeutics agreed to merge. The deal will take privately-held Tarveda public.
Prev Next